Drugs / MK-6194
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT06821334 | Apr → Aug 2024 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT06649877 | Mar → Jul 2023 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT05450198 | Aug 2022 → May 2024 | atopic eczema | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT04924114 | Oct 2021 → Jan 2024 | ulcerative colitis | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 22 trials · 1 missed | ||||||
| Phase 2 | NCT06161116 | Dec 2023 → Jul 2025 | systemic lupus erythematosus | Merck Sharp & Dohme LLC | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT06113328 | Nov 2023 → Mar 2025 | vitiligo | Merck Sharp & Dohme LLC | Terminated | Missed primary Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-6194 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05450198 ↗ |
| Route | Subcutaneous | “Subcutaneous injection” NCT04924114 ↗ |